GlaxoSmithKline
GlaxoSmithKline lowers dosage to protect your heart
- Thu, 07/05/2012 - 9:33am
GlaxoSmithKline LLC has lowered Zofran’s dosage label after preliminary results of a clinical study revealed a risk of developing an abnormal heart rhythm.
-
Lucentis approved for diabetic macular edema
- Aug 14, 2012
-
Newly approved Myrbetriq eases overactive bladder condition
- Jul 11, 2012
-
FDA advisory committee ordered to conduct new Yaz and Yasmin meeting
- Jan 18, 2012
-
FDA OKs new meningitis vaccine for babies
- Jun 15, 2012
-
Ariad asks FDA for priority review of leukemia drug
- Jul 31, 2012
-
Bayer confirms lawsuit settlements in quarterly statement
- May 1, 2012
-
FDA issues warning after codeine kills children post-surgery
- Aug 16, 2012
-
Artificial retina gives sight to blind mice
- Aug 16, 2012
-
Lucentis approved for diabetic macular edema
- Aug 14, 2012
-
Mayo Clinic: Patients in the dark about prescriptions
- Aug 9, 2012
-
Hospital's plan to prevent painkiller abuse
- Aug 8, 2012
-
Alzheimer's drug disappoints
- Aug 8, 2012
Pradaxa heart attack Bayer fentanyl patch Accutane Travel liver damage Fosamax Inspiration lorcaserin Urban Avaira diet pill Tutorials hormone replacement therapy Drugs lawsuit Zimmer diet drug coumadin Photography generic HIV test D.C. Design Johnson & Johnson blood thinner pulomonary embolism Avandia Nexavar
More Dangerous Drug News
Get News Updates By Email
@ConsumerDrugRep Tweets
Archives
- June 2011 (3)
- September 2011 (1)
- October 2011 (3)
- November 2011 (5)
- December 2011 (25)
- January 2012 (8)
- February 2012 (24)
- March 2012 (20)
- April 2012 (6)
- May 2012 (12)